Sophia Genetics: the first European bioinformatic company allowed to analyze clinical genetic data

17/09/2014 - 2 minutes

Sophia Genetics has become the first European company to obtain a CE-IVD mark allowing the use of their bioinformatic algorithms to analyse clinical data obtained through Next Generation Sequencing. This certification is an important step in making these in the standard use of routine genetic testing and clinical diagnosis. It brings Sophia Genetics’ world-leading Data Driven Medicine platform to a wider market.

Sophia Genetics offers a software as a service, which can keep safe all the genomic data from patients and give results of genetic tests data. Their software, called dropGen is able to use genetic sequences, analyse them and deliver precise data visualization to clinicians. The following figure shows all the process:

Sophia Genetics dropGen NGS

The CE-mark (CE-IVD) indicates that an In Vitro Diagnostics (IVD) device complies with the European IVD Directive, and that the device can be legally commercialized and distributed in the EU.

Jurgi Camblong, CEO of Sophia Genetics, said:

“The barrier to wider adoption of Next Generation Sequencing (NGS) data for the routine genetic testing of patients has historically been the challenge associated with analysing data.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member